Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease chronic myeloproliferative disease
Symptom C0040053|thrombosis
Sentences 14
PubMedID- 25191727 Clinical risk factors of thrombosis in patients with ph-negative myeloproliferative neoplasms, who had experienced radiation exposure due to the chornobyl accident.
PubMedID- 23820940 In spite of their recognized risk of thrombosis, patients with myeloproliferative neoplasms (mpn) show little or no abnormalities of traditional coagulation tests, perhaps because these are unable to represent the balance between pro- and anticoagulants nor the effect of platelets and blood cells.
PubMedID- 25840747 We examined a consecutive series of 29 patients with myeloproliferative neoplasms (mpns) associated with splanchnic vein thrombosis (svt) in order to evaluate their bone marrow morphology and identify possible associations between histological findings and clinical features.
PubMedID- 23031663 It is unclear whether the somatic jak2v617f mutation, a marker for chronic myeloproliferative disorders (mpds), is associated with cerebral venous thrombosis (cvt) in the absence of mpd.
PubMedID- 24610470 thrombosis in myeloproliferative neoplasms.
PubMedID- 21282719 Pathophysiology of thrombosis in myeloproliferative neoplasms.
PubMedID- 25042466 Cerebral vein thrombosis in patients with philadelphia-negative myeloproliferative neoplasms.
PubMedID- 21151606 Hemoglobin of 13.8 g/dl or lower, white blood cells count of 7.8×109/l or lower, and platelet count of 400×109/l or lower (adjusted odds ratio = 4.43, 95% ci = 1.45–13.49) thirteen patients with splanchnic vein thrombosis non associated with myeloproliferative neoplasms were recruited as controls.
PubMedID- 20052751 Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain.
PubMedID- 22826442 thrombosis in myeloproliferative neoplasms with jak2v617f mutation.
PubMedID- 25970015 Risk of thrombosis in patients with myeloproliferative neoplasms and elevated platelet counts.
PubMedID- 21986846 How to manage thrombosis in myeloproliferative neoplasms.
PubMedID- 21505581 These explain thrombophilia and increased risk of thrombosis in patients with chronic myeloproliferative disorders, particularly those with jak2 mutation present.
PubMedID- 24084459 Aim: the aim of this study was to examine the jak2 v617f, the g1691a allele of factor v, and the g20210a prothrombin gene mutation status, and their predictive value for thrombosis in patients with ph-negative myeloproliferative neoplasms (mpn) in ukraine, with special emphasize to patient exposed to ionizing radiation due to the chernobyl accident.

Page: 1